Paradox Immunotherapeutics
Paradox Immunotherapeutics is a preclinical-stage biotech company focused on developing innovative antibody therapies to treat protein misfolding diseases, such as amyloidosis. Their approach involves using a unique platform to develop antibodies that selectively target misfolded proteins while leaving healthy proteins untouched. The company is developing treatments for immunoglobulin light chain amyloidosis and leukocyte chemotactic factor 2 amyloidosis.
Funding Round:
Funding Amount: $10M
Date: 25-Feb-2025
Investors: SymBiosis
Markets: Biotech, Pharmaceuticals
HQ: Toronto, Ontario, Canada
Founded: 2019
Website: https://www.paradoximmuno.com
LinkedIn: https://www.linkedin.com/company/paradoximmuno/
Twitter: https://twitter.com/ParadoxImmuno
Crunchbase: https://www.crunchbase.com/organization/paradox-immunotherapeutics-inc
Leave a Comment
Comments
No comments yet.